Spotlight Series on Hepatitis C


What Are the Hepatitis C Genotypes?

October 24, 2016


The Future

The Future

The approval of sofosbuvir/velpatasvir as Epclusa, a pan-genotypic regimen, will eliminate the need for genotype testing prior to treatment and could reduce treatment errors, said Vargas. Now that all genotypes are fairly well covered by available direct-acting antivirals, the next treatment challenge to address will be those small numbers of patients who fail treatment, he continued. All of the direct-acting antivirals approved today have at least a 95% cure rate, which means some patients will need to be re-treated.

Gilead Sciences, the makers of Epclusa, are planning to combine it with a new experimental drug called voxilaprevir, and this combination might one day be an option for patients who don't respond to currently available treatments, Vargas said. Moreover, Epclusa is essentially a stepping-stone in Gilead's plans for a future three-drug regimen that is pan-genotypic and does not include ribavirin, said Korenblat.

Merck, the makers of elbasvir/grazoprevir (Zepatier), are also testing the combination of elbasvir/grazoprevir and a "nuc" drug that will fill the same role as Gilead's sofosbuvir, the backbone of Harvoni and Epclusa. Overall, Vargas is impressed with the breakneck pace of drug development in hepatitis C. "I never would have imagined that we would be at this very nice space this early," he said. "The future is shaping itself very nicely."

Credit: Devonyu for iStock via Thinkstock.

This article was provided by

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.